Tags: respiratory | infection | drug | brincidofovir | adenovirus | effective

Drug Cuts Respiratory Infection Deaths in Half

Wednesday, 08 Oct 2014 12:18 PM


Chimerix Inc said its experimental oral antiviral improved the survival rate of patients with a certain type of respiratory infection, according to preliminary data from a late-stage study.
The news on the drug, used earlier this week to treat the first Ebola patient diagnosed in the United States, sent the company's shares up 6 percent to $35.25 in premarket trading.
Chimerix said the data on the drug, brincidofovir, was based on 48 evaluable patients with adenovirus, a common virus that causes respiratory illnesses.
The company said the 48 patients who took brincidofovir had a mortality rate of 35 percent, compared with historic rates of up to 80 percent in the first month after diagnosis.
A majority of the patients also had suppression or clearance of adenovirus from the blood, Chimerix said.
 

© 2017 Thomson/Reuters. All rights reserved.

   
1Like our page
2Share
Health-News
Chimerix Inc said its experimental oral antiviral improved the survival rate of patients with a certain type of respiratory infection, according to preliminary data from a late-stage study. The news on the drug, used earlier this week to treat the first Ebola patient...
respiratory, infection, drug, brincidofovir, adenovirus, effective
131
2014-18-08
Wednesday, 08 Oct 2014 12:18 PM
Newsmax Inc.
 

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved